LS CancerDiag Oy

What LS CancerDiag Oy does

LS CancerDiag Oy is a Helsinki-based diagnostics company founded in 2013 as a spin-off from the University of Helsinki with the stated mission of reducing cancer mortality through earlier identification of Lynch syndrome (hereditary mismatch repair deficiency). The company's flagship product, DiagMMR®, is a quantitative functional assay designed to detect MMR deficiency in non-malignant tissue samples, providing predictive diagnosis before tumors develop. It targets an inherited condition affecting approximately 1 in 279 people globally, in which carriers face up to 80% lifetime cancer risk and more than 2 million new cancer cases annually should be tested for the syndrome. The company has recently introduced a sub-brand identity, 'Lynsight', while continuing to commercialize the DiagMMR® product line.

The DiagMMR® test is a wet-lab functional assay rather than a sequencing-based genomic test, which allows it to deliver actionable results without requiring underlying clinical data or interpretation of variants of uncertain significance. Clinical validation studies with Helsinki and Jyväskylä central hospitals (initiated 2016, completed 2018) demonstrated 100% specificity, with work later published in Cancer Research Communications (March 2023). The technology is protected by patents (first granted in Australia in 2015), holds CE marking as an in vitro diagnostic medical device (2019), and the company operates under ISO 13485 certification (2022). Product differentiation rests on three pillars: a functional (not genetic) test architecture, predictive timing (pre-tumor detection), and ease of use (minimal tissue sample, no prior mutation knowledge required).

LS CancerDiag operates a B2B model, selling CE-marked IVD devices and laboratory testing services to hospitals, clinical laboratories, and other healthcare providers. The company launched commercially in Finland in 2019 through two distribution partners and is now executing a US market entry funded by a €5.4M round raised via Springvest in 2023. Pricing is quote-based with multi-year contracts, revenue figures are not publicly disclosed, and the company maintains a compact team of approximately 12 specialists anchored by founder Prof. Minna Nyström from headquarters at Arabiankatu 12, Helsinki.

Name

LS CancerDiag Oy

Legal name

LS CancerDiag Ltd

Website

https://lscancerdiag.com

Company type

Private

Founded year

2013

Operating status

Operating

Headcount range

1–10 employees

Short description

LS CancerDiag Oy, based in Helsinki, markets DiagMMR®, a patented functional assay that identifies Lynch syndrome carriers by detecting mismatch repair deficiency. The company sells CE-marked IVD devices to Finnish healthcare providers and is expanding into the US market.

Ownership category

akta.pro rank

Product category

Hereditary Cancer Diagnostics

NAICS

Medical Laboratories (621511), In-Vitro Diagnostic Substance Manufacturing (325413)

SIC

In Vitro & In Vivo Diagnostic Substances (2835), Services-Medical Laboratories (8071)

akta.pro primary industry

Oncology Diagnostics (tumor profiling, MRD, liquid biopsy) (HLAAALAE)

akta.pro secondary industry

Genetic, Cytogenetic & Prenatal Screening IVD (HLAHAAAI)

Keywords

• Hereditary cancer diagnostics
• Lynch syndrome testing
• In vitro diagnostics
• Mismatch repair assay
• Functional predictive diagnostics

Headquarters

HQ city

Helsinki

HQ country

Finland

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain

Revenue model

1. Diagnostic Testing Services: DiagMMR in vitro diagnostic test sold to healthcare facilities, clinical laboratories, and hospitals for Lynch syndrome screening and diagnosis.
2. CE Marked IVD Medical Device: Sale of CE-marked in vitro diagnostics medical device for MMR deficiency detection in European markets.

Pricing tiers

Go-to-market motion1 record

Distribution channels3 records

Marketing channels8 records

Core offering

LS CancerDiag develops, manufactures, and sells DiagMMR®, a CE-marked in vitro diagnostic (IVD) functional test for detecting mismatch repair (MMR) deficiency to identify individuals with Lynch syndrome before tumors develop. The company provides the test as a CE-marked IVD medical device to healthcare facilities, clinical laboratories, and hospitals in the Finnish market, with planned expansion to the United States.

Product overview

LS CancerDiag Oy offers DiagMMR® as its core diagnostic product, a functional test for detecting mismatch repair (MMR) deficiency to identify Lynch syndrome carriers. The company has transitioned its brand to Lynsight while continuing to provide the DiagMMR® test, which is designed to be a predictive diagnostic tool enabling preventive follow-up for affected mutation carriers at high risk for developing Lynch syndrome-related cancers.

Differentiator

Problem solved

Functional benefit

Products and services

• DiagMMR® DiagMMR® is a functional in vitro diagnostic (IVD) test that detects mismatch repair (MMR) deficiency to identify individuals with Lynch syndrome before tumors develop. It is a predictive test that analyzes MMR functionality directly from tissue samples, providing actionable results without requiring knowledge of specific inherited mutations. Sold to healthcare facilities, clinical laboratories, and hospitals as a CE-marked IVD medical device.
• Lynsight Lynsight is the new corporate brand identity of LS CancerDiag, under which the DiagMMR® diagnostic product continues to be offered. It represents the company's evolution while continuing to provide the predictive MMR-deficiency diagnostic for Lynch syndrome detection.

Quantifiable outcome

• 100% specificity in detecting inherited MMR deficiency
• +2 more outcomes

Named customers3 records

Segments3 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

Ten partnerships are on record, tiered supporting and core.

• EIT Health Bridgehead AcceleratorsupportingStrategic or Co-development Partner · 1 January 2020Selected for EIT Health Bridgehead Global Accelerator program in 2020 to support international expansion beyond Europe.
• X-Europe AcceleratorsupportingGTM or Marketing Partner · 1 January 2020Selected for X-Europe Accelerator program in 2020 to support growth and scaling of operations.
• Nordic Network for Entrepreneurship (NOME)supportingStrategic or Co-development Partner · 1 January 2020Selected for Nordic Network for Entrepreneurship (NOME) program in 2020 for entrepreneurship and business development support.
• Finnish Distribution PartnerscoreChannel Partner/ Reseller/ Distributor · 1 January 2019Two distribution partners in Finland launched DiagMMR in the domestic market in 2019, reselling the CE-marked IVD diagnostic test to healthcare facilities.
• StartUp HealthsupportingGTM or Marketing Partner · 1 January 2016Joined StartUp Health accelerator program in 2016 for entrepreneurship support and global health innovation networking.
• University of HelsinkicoreStrategic or Co-development PartnerLS CancerDiag was founded as a spin-off from the University of Helsinki in 2013, with founding CEO Prof. Minna Nyström leading the research. The ERC grant supported the initial technology development. Ongoing research collaboration for Lynch syndrome diagnostics.
• InvesthorizonsupportingGTM or Marketing PartnerInvesthorizon EU program logo displayed, providing investor readiness and funding support for deeptech companies.
• ProHEALTH AcceleratorsupportingGTM or Marketing PartnerProHEALTH Accelerator program logo displayed supporting health technology innovation and startup growth.
• Helsinki Central HospitalsupportingImplementation/ SI/ Consulting PartnerClinical validation study initiated in 2016 with Helsinki central hospital for DiagMMR test validation.
• Jyväskylä Central HospitalsupportingImplementation/ SI/ Consulting PartnerClinical validation study initiated in 2016 with Jyväskylä central hospital for DiagMMR test validation.

Scale indicators6 records

Recent moves8 records

Expansion highlights6 records

Broad incumbents

• Myriad Genetics: Myriad is a long-established leader in hereditary cancer genetic testing (BRACAnalysis, myRisk) and competes directly for the same Lynch syndrome and broader hereditary cancer screening market that DiagMMR targets, with deeper reimbursement and clinician relationships.
• Natera: Natera operates a large molecular diagnostics platform spanning reproductive, oncology, and hereditary cancer testing, with significant scale advantages that could pressure smaller functional assay entrants like DiagMMR.
• Invitae (Labcorp): Invitae, now part of Labcorp, offers broad hereditary cancer genetic testing panels including Lynch syndrome screening, representing a major scaled competitor in the same clinical indication.
• GeneDx: GeneDx provides hereditary cancer and rare disease genetic testing at scale, including Lynch syndrome and MMR gene analysis, competing for similar hospital and reference lab customers.
• NeoGenomics: NeoGenomics is a specialized oncology testing laboratory offering hereditary cancer panels alongside solid tumor profiling, overlapping with DiagMMR's oncology diagnostics positioning and clinical customers.
• Foundation Medicine: Foundation Medicine is a leader in comprehensive genomic profiling for oncology with broad hospital and biopharma partnerships; its tumor-focused assays offer an alternative oncology diagnostic pathway to DiagMMR's predictive hereditary testing approach.
• Caris Life Sciences: Caris provides molecular profiling and hereditary cancer testing for oncology, overlapping with DiagMMR's oncology diagnostics market and competing for hospital lab contracts.

Direct peers

• Ambry Genetics: Ambry is a leading clinical genetic testing laboratory with extensive hereditary cancer panels (including Lynch syndrome), competing head-to-head with DiagMMR for hospital and clinician testing volume.
• Color Health: Color offers hereditary cancer genetic testing including Lynch syndrome panels to healthcare systems and employers, competing for the same preventive screening and population health use cases that DiagMMR targets.

Emerging players

• PreventionGenetics: PreventionGenetics (part of Exact Sciences) offers hereditary cancer genetic testing panels including Lynch syndrome, competing for clinical lab partnerships and hereditary cancer screening workflows.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks5 records

Key highlights6 records

Customer concentration

• Xx.com/lscancerdiag
• YouTubeyoutube.com/@lscancerdiag
• Facebookfacebook.com/DiagMMR
• LinkedInlinkedin.com/company/lscancerdiag

Compliance3 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles12 records

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about LS CancerDiag Oy